Page 91 - GTM-4-2

Global Translational Medicine Angiotensinogen in liver steatosis

37. Nikolova-Karakashian M, Karakashian A, Rutkute K. Role 48. Dong R, Zhang D, Han B, et al. DTL is a novel downstream
of neutral sphingomyelinases in aging and inflammation. gene of E2F1 that promotes the progression of hepatocellular
Subcell Biochem. 2008;49:469-486. carcinoma. Curr Cancer Drug Targets. 2023;23:817-828.
doi: 10.1007/978-1-4020-8831-5_18 doi: 10.2174/1568009623666230511100246
38. Summers SA. Ceramides: Nutrient signals that drive 49. Borlado LR, Mendez J. CDC6: From DNA replication to
hepatosteatosis. J Lipid Atheroscler. 2020;9:50-65. cell cycle checkpoints and oncogenesis. Carcinogenesis.
doi: 10.12997/jla.2020.9.1.50 2008;29:237-243.
39. El-Amouri S, Karakashian A, Bieberich E, Nikolova- doi: 10.1093/carcin/bgm268
Karakashian M. Regulated translocation of neutral 50. Shi Y, Yan F, Wang F, Pan L. MiR-128-3p suppresses
sphingomyelinase-2 to the plasma membrane drives tumor proliferation and metastasis via targeting CDC6 in
insulin resistance in steatotic hepatocytes. J Lipid Res. hepatocellular carcinoma cells. Tissue Cell. 2021;72:101534.
2023;64:100435.
doi: 10.1016/j.tice.2021.101534
doi: 10.1016/j.jlr.2023.100435
51. Uuskula-Reimand L, Wilson MD. Untangling the roles of
40. Geilen CC, Wieder T, Orfanos CE. Ceramide signalling: TOP2A and TOP2B in transcription and cancer. Sci Adv.
regulatory role in cell proliferation, differentiation and 2022;8:eadd4920.
apoptosis in human epidermis. Arch Dermatol Res.
1997;289:559-566. doi: 10.1126/sciadv.add4920
doi: 10.1007/s004030050240 52. Wang T, Lu J, Wang R, Cao W, Xu J. TOP2A promotes
proliferation and metastasis of hepatocellular carcinoma
41. Hajduch E, Lachkar F, Ferre P, Foufelle F. Roles of ceramides regulated by miR-144-3p. J Cancer. 2022;13:589-601.
in non-alcoholic fatty liver disease. J Clin Med. 2021;10:792.
doi: 10.7150/jca.64017
doi: 10.3390/jcm10040792
53. Assy N, Minuk GY. Liver regeneration: methods for
42. Raichur S, Brunner B, Bielohuby M, et al. The role of C16:0 monitoring and their applications. J Hepatol. 1997;
ceramide in the development of obesity and type 2 diabetes: 26:945-952.
CerS6 inhibition as a novel therapeutic approach. Mol
Metab. 2019;21:36-50. doi: 10.1016/s0168-8278(97)80266-8
doi: 10.1016/j.molmet.2018.12.008 54. Huang Z, Zhou P, Li S, Li K. Prediction of the Ki-67 marker
index in hepatocellular carcinoma based on dynamic
43. Saddoughi SA, Ogretmen B. Diverse functions of ceramide contrast-enhanced ultrasonography with sonazoid. Insights
in cancer cell death and proliferation. Adv Cancer Res. Imaging. 2022;13:199.
2013;117:37-58.
doi: 10.1186/s13244-022-01320-6
doi: 10.1016/B978-0-12-394274-6.00002-9
55. Trauner M, Fuchs CD. Novel therapeutic targets for
44. Rossi M, Duan S, Jeong YT, et al. Regulation of the cholestatic and fatty liver disease. Gut. 2022;71:194-209.
CRL4(Cdt2) ubiquitin ligase and cell-cycle exit by the
SCF(Fbxo11) ubiquitin ligase. Mol Cell. 2013;49:1159-1166. doi: 10.1136/gutjnl-2021-324305
doi: 10.1016/j.molcel.2013.02.004 56. Cast A, Kumbaji M, D’Souza A, et al. Liver proliferation is an
essential driver of fibrosis in mouse models of nonalcoholic
45. Huh J, Piwnica-Worms H. CRL4(CDT2) targets CHK1 for fatty liver disease. Hepatol Commun. 2019;3:1036-1049.
PCNA-independent destruction. Mol Cell Biol. 2013;33:
213-226. doi: 10.1002/hep4.1381
doi: 10.1128/MCB.00847-12 57. Sun X, Kaufman PD. Ki-67: More than a proliferation
marker. Chromosoma. 2018;127:175-186.
46. Liu Z, Yang G, Yi X, et al. Osteopontin regulates the growth
and invasion of liver cancer cells via DTL. Oncol Lett. doi: 10.1007/s00412-018-0659-8
2023;26:476. 58. Mrouj K, Andres-Sanchez N, Dubra G, et al. Ki-67
doi: 10.3892/ol.2023.14064 regulates global gene expression and promotes sequential
stages of carcinogenesis. Proc Natl Acad Sci U S A.
47. Chen ZX, Mu MY, Yang G, et al. Hypoxia-induced DTL 2021;118:e2026507118.
promotes the proliferation, metastasis, and sorafenib
resistance of hepatocellular carcinoma through ubiquitin- doi: 10.1073/pnas.2026507118
mediated degradation of SLTM and subsequent Notch 59. Li Z, Wang R, Qiu C, et al. Role of DTL in hepatocellular
pathway activation. Cell Death Dis. 2024;15:734.
carcinoma and its impact on the tumor microenvironment.
doi: 10.1038/s41419-024-07089-4 Front Immunol. 2022;13:834606.

Volume 4 Issue 2 (2025) 83 doi: 10.36922/gtm.6027